MX2024001326A - Composicion farmaceutica de anticuerpo anti-pd-1 y uso de la misma. - Google Patents
Composicion farmaceutica de anticuerpo anti-pd-1 y uso de la misma.Info
- Publication number
- MX2024001326A MX2024001326A MX2024001326A MX2024001326A MX2024001326A MX 2024001326 A MX2024001326 A MX 2024001326A MX 2024001326 A MX2024001326 A MX 2024001326A MX 2024001326 A MX2024001326 A MX 2024001326A MX 2024001326 A MX2024001326 A MX 2024001326A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- seq
- antibody
- antigen
- antibody pharmaceutical
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 6
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 238000002347 injection Methods 0.000 abstract 2
- 239000007924 injection Substances 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 102100023990 60S ribosomal protein L17 Human genes 0.000 abstract 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención proporciona una composición farmacéutica de anticuerpo anti-PD-1 estable y el uso de la misma. La composición farmacéutica comprende un tampón y un anticuerpo anti-PD-1 o un fragmento de unión a antígeno del mismo; en donde el anticuerpo anti-PD-1 o el fragmento de unión a antígeno del mismo tiene una concentración de aproximadamente 100-250 mg/ml y comprende una LCDR1, una LCDR2 y una LCDR3 que tienen las secuencias de aminoácidos establecidas en la SEQ ID NO: 1, SEQ ID NO: 2 y SEQ ID NO: 3, respectivamente, y una HCDR1, una HCDR2 y una HCDR3 que tienen secuencias de aminoácidos establecidas en la SEQ ID NO: 4, SEQ ID NO: 5 y SEQ ID NO: 6, respectivamente; y en donde la composición farmacéutica tiene un pH de aproximadamente 5.0-6.5. La presente invención también proporciona una inyección que comprende la composición farmacéutica y el uso de la composición farmacéutica y la inyección en la preparación de un medicamento para tratar una enfermedad o trastorno eliminando, inhibiendo o reduciendo la actividad de PD-1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110863978 | 2021-07-29 | ||
| PCT/CN2022/108825 WO2023006055A1 (en) | 2021-07-29 | 2022-07-29 | Anti-pd-1 antibody pharmaceutical composition and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024001326A true MX2024001326A (es) | 2024-02-15 |
Family
ID=85086307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024001326A MX2024001326A (es) | 2021-07-29 | 2022-07-29 | Composicion farmaceutica de anticuerpo anti-pd-1 y uso de la misma. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240342083A1 (es) |
| EP (1) | EP4376809A4 (es) |
| JP (1) | JP2024528724A (es) |
| CN (1) | CN116019907A (es) |
| AR (1) | AR126614A1 (es) |
| AU (1) | AU2022320670A1 (es) |
| CA (1) | CA3227991A1 (es) |
| CL (1) | CL2024000232A1 (es) |
| MX (1) | MX2024001326A (es) |
| UY (1) | UY39878A (es) |
| WO (1) | WO2023006055A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202508635A (zh) * | 2023-07-07 | 2025-03-01 | 日商長瀨微態生物科技股份有限公司 | 蛋白質之變性抑制用組成物 |
| WO2025113598A1 (zh) * | 2023-12-01 | 2025-06-05 | 齐鲁制药有限公司 | 稳定的混合抗体的药物组合物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104250302B (zh) * | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| EP3601338A4 (en) * | 2017-03-29 | 2020-12-16 | Celgene Corporation | FORMULATIONS INCLUDING PROTEINS BINDING PD-1 AND THEIR PREPARATION METHODS |
| BR112019023846A2 (pt) * | 2017-05-16 | 2020-06-09 | Jiangsu Hengrui Medicine Co | composição farmacêutica de anticorpo de pd-l1 e uso da mesma |
| US12150990B2 (en) * | 2017-11-02 | 2024-11-26 | Nanjing Shunxin Pharmaceutical Co., Ltd. | Pharmaceutical composition of humanized monoclonal anti-PD-L1 antibody |
| CN112972675A (zh) * | 2018-09-07 | 2021-06-18 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在治疗肿瘤中的用途 |
| WO2020111018A1 (ja) * | 2018-11-27 | 2020-06-04 | 小野薬品工業株式会社 | 免疫チェックポイント阻害薬およびｆｏｌｆｉｒｉｎｏｘ療法との併用によるがん治療 |
| CN112741804A (zh) * | 2019-10-31 | 2021-05-04 | 上海君实生物医药科技股份有限公司 | 含有抗pd-l1抗体的稳定制剂 |
| WO2022152245A1 (zh) * | 2021-01-14 | 2022-07-21 | 上海君实生物医药科技股份有限公司 | 抗tigit抗体药物组合物及其用途 |
-
2022
- 2022-07-29 CA CA3227991A patent/CA3227991A1/en active Pending
- 2022-07-29 AU AU2022320670A patent/AU2022320670A1/en active Pending
- 2022-07-29 WO PCT/CN2022/108825 patent/WO2023006055A1/en active Application Filing
- 2022-07-29 US US18/291,935 patent/US20240342083A1/en active Pending
- 2022-07-29 CN CN202210929845.3A patent/CN116019907A/zh active Pending
- 2022-07-29 AR ARP220102031A patent/AR126614A1/es unknown
- 2022-07-29 JP JP2024505015A patent/JP2024528724A/ja active Pending
- 2022-07-29 UY UY0001039878A patent/UY39878A/es unknown
- 2022-07-29 MX MX2024001326A patent/MX2024001326A/es unknown
- 2022-07-29 EP EP22848659.3A patent/EP4376809A4/en active Pending
-
2024
- 2024-01-26 CL CL2024000232A patent/CL2024000232A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3227991A1 (en) | 2023-02-02 |
| JP2024528724A (ja) | 2024-07-30 |
| AU2022320670A1 (en) | 2024-03-14 |
| US20240342083A1 (en) | 2024-10-17 |
| WO2023006055A1 (en) | 2023-02-02 |
| EP4376809A1 (en) | 2024-06-05 |
| UY39878A (es) | 2023-02-28 |
| EP4376809A4 (en) | 2025-06-04 |
| AR126614A1 (es) | 2023-10-25 |
| CN116019907A (zh) | 2023-04-28 |
| CL2024000232A1 (es) | 2024-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2486198C2 (ru) | Антиген, ассоциированный с ревматоидным артритом | |
| CL2024000232A1 (es) | Composición farmacéutica de anticuerpo anti-pd-1 y uso de la misma | |
| NZ706986A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
| JP6243521B2 (ja) | オンコスタチンｍ受容体抗原結合タンパク質 | |
| NZ590863A (en) | Anti-hepcidin-25 selective antibodies and uses thereof | |
| NZ600768A (en) | Human antibodies to human angiopoietin-like protein 4 | |
| NZ592436A (en) | Treatment with anti-alpha2 integrin antibodies | |
| NZ598391A (en) | Anti-hepcidin antibodies and uses thereof | |
| IL259036A (en) | asct2-specific binding molecules and their uses | |
| NZ600512A (en) | Neutralizing prolactin receptor antibodies and their therapeutic use | |
| HRP20231021T1 (hr) | Protutijela anti-cd38 za liječenje akutne limfoblastične leukemije | |
| RU2013143358A (ru) | Анти-fgfr4 антитела и способы их применения | |
| RU2014150548A (ru) | Терапевтическое средство от зуда | |
| CN115666649A (zh) | 一种新型冠状病毒抗体的药物组合物及其用途 | |
| RU2019139093A (ru) | Фармацевтическая композиция на основе антитела к pd-l1 и ее применение | |
| JP2023055904A5 (es) | ||
| PE20240363A1 (es) | Anticuerpos anti-ccr8 y usos de los mismos | |
| RU2017144629A (ru) | Тромбин-связывающие молекулы антител и их применение | |
| MX2023009693A (es) | Anticuerpo anti-peptidilarginina desiminasa 4 (pad4) novedoso. | |
| AR124067A2 (es) | Formulaciones estables que comprenden un anticuerpo biespecífico para egfr / c-met | |
| PE20230116A1 (es) | Formulacion de anticuerpos | |
| FI3630177T3 (fi) | Hoitoparadigma anti-cd19-vasta-aineen ja venetoklaksin yhdistelmähoidolle | |
| MX2024015541A (es) | Anticuerpo anti-cldn18.2, y composicion farmaceutica y uso de la misma | |
| AR082641A1 (es) | Composiciones de anticuerpo anti-vegfr-3 | |
| AR074398A1 (es) | Anticuerpo nonoclonal o su fragmento de union a antigeno polinucleotido vector de expresion recombinante y celula huesped transformada correspondientes su uso para la preparacion de un medicamento util para el tratamiento o prevencion de anemia, composicion farmaceutica que lo comprende y proceso pa |